A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…
The next generation of CAR-T therapies is already emerging.